View Older Stories View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel Raises Price Target on Alnylam Pharmaceuticals (ALNY) to $345
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $342 at Scotiabank
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $345 at Stifel
-
Redburn-Atlantic Starts Alnylam Pharmaceuticals (ALNY) at Buy
-
Alnylam Pharma (ALNY) Announces FDA Approval of Qfitlia
-
Bernstein on Alnylam Pharmaceuticals (ALNY): 'A Strident but Unconvincing Bear Case'
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Incrementally More Positive on ALNY and Remain Buyers'
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight
-
Alnylam Pharma (ALNY) call put ratio 1.9 calls to 1 put on 7500 contracts as share price up 10%
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $338 at Scotiabank
-
Cantor Fitzgerald Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $390 at Canaccord Genuity
-
Alnylam Pharma (ALNY) announces FDA approval of AMVUTTRA
-
Alnylam Pharma (ALNY) Halted, News Pending
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Alnylam Pharma (ALNY) Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC on Alnylam Pharmaceuticals (ALNY): 'We Would Be Buyers Ahead Of Upcoming PDUFA Date'
-
Piper Sandler Reiterates Overweight on Alnylam Pharmaceuticals (ALNY), 'Confident in AMVUTTRA Approval'
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at H.C. Wainwright
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $385 at Canaccord Genuity
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Our Expert Sees A Favorable Set-up'
-
Goldman Makes Monthly Adjustment to Director's Cut Conviction List
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) After a Solid TTR Beat
-
Alnylam Pharma (ALNY) Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance
-
Barclays shares outlook for Biotech in 2025, names preferred stocks
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Announces U.S. FDA Acceptance of sNDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Wolfe Research Downgrades Alnylam Pharmaceuticals (ALNY) to Underperform
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $371 at TD Cowen
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Piper Sandler Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
Oppenheimer Reiterates Perform Rating on Alnylam Pharmaceuticals (ALNY)
-
Citi Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

